Showing results (1-10 of 181) with videos related to

Sort By:
Pageof 19
Clinical Nuclear Medicine|December 19, 1998
Proliferative myositis: a case of a pseudomalignant processM Gysen, S Stroobants, L Mortelmans
Gynecologic and Obstetric Investigation|July 17, 2003
Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancerO Drieskens, S Stroobants, M Gysen, et al.
Melanoma Research|October 24, 2002
18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impactM Stas, S Stroobants, P Dupont, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 26, 2008
Non-Hodgkin lymphoma: retrospective study on the cost-effectiveness of early treatment response assessment by FDG-PETG Moulin-Romsee, K Spaepen, S Stroobants, et al.
IEEE Transactions on Medical Imaging|July 23, 1999
Simultaneous maximum a posteriori reconstruction of attenuation and activity distributions from emission sinogramsJ Nuyts, P Dupont, S Stroobants, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2001
Clinical value of [(18)F]fluoro-deoxyglucose positron emission tomography for patients with fever of unknown originD Blockmans, D Knockaert, A Maes, et al.
European Radiology|May 10, 2006
Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CTW De Wever, S Ceyssens, L Mortelmans, et al.
Rheumatology (Oxford, England)|June 17, 1999
New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomographyD Blockmans, A Maes, S Stroobants, et al.
British Journal of Haematology|November 13, 2001
Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?K Spaepen, S Stroobants, P Dupont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancerP Flamen, S Stroobants, E Van Cutsem, et al.
Pageof 19